FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119492218> ?p ?o ?g. }

• W3119492218 abstract "Abstract Background Macular edema secondary to retinal vein occlusion (RVO) is an important cause of loss of vision. Intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) are the standard of care in this disease, as shown in numerous randomized controlled trials. The purpose of this study was to study the efficacy and safety of ranibizumab, an anti-VEGF agent, in the real-world setting. Methods This was 48 weeks, open-label, prospective, multicentre, observational study. Patients diagnosed with ME secondary to RVO were treated with IVI of Ranibizumab 0.5 mg in real-world conditions. Efficacy was measured by improvement seen in best-corrected visual acuity (BCVA) in terms of Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores and change in central retinal thickness (CRT) measured by optical coherence tomography. Results One hundred eyes of 100 patients (79 with branch retinal vein occlusion and 21 with central retinal vein occlusion) were recruited in the study. The mean (standard deviation, SD) BCVA was 52.8 (21.99) letters at baseline and 62.3 (24.40) letters at week 48. From baseline, there was a significant improvement in BCVA by 7.7 letters ( p = 0.001) at 48 weeks. The mean (SD) of CRT was 479.9 (216.25) μm at baseline and it decreased significantly to 284.9 (171.35) μm at week 48 ( p < 0.001). During the study period, the average number of intravitreal injections was 3.5 per patient. There was no report of endophthalmitis in any eye. Conclusions Ranibizumab is well tolerated and effective in treating macular edema secondary to RVO in real-world clinical settings. However, there is under-treatment compared to controlled clinical trials, and the gain in vision is sub-optimal with under-treatment. Trial registration Clinical Trials Registry - India: CTRI/2015/07/005985 ." @default.
• W3119492218 created "2021-01-18" @default.
• W3119492218 creator A5000602417 @default.
• W3119492218 creator A5002540731 @default.
• W3119492218 creator A5020672815 @default.
• W3119492218 creator A5022949376 @default.
• W3119492218 creator A5023793303 @default.
• W3119492218 creator A5028908432 @default.
• W3119492218 creator A5041792266 @default.
• W3119492218 creator A5049008273 @default.
• W3119492218 creator A5075207987 @default.
• W3119492218 creator A5079525467 @default.
• W3119492218 date "2021-01-12" @default.
• W3119492218 modified "2023-10-01" @default.
• W3119492218 title "Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab" @default.
• W3119492218 cites W1774049372 @default.
• W3119492218 cites W1971399814 @default.
• W3119492218 cites W1977995451 @default.
• W3119492218 cites W2019435952 @default.
• W3119492218 cites W2025524636 @default.
• W3119492218 cites W2053733959 @default.
• W3119492218 cites W2094007374 @default.
• W3119492218 cites W2141529239 @default.
• W3119492218 cites W2285674438 @default.
• W3119492218 cites W2323650168 @default.
• W3119492218 cites W2475343081 @default.
• W3119492218 cites W2575186639 @default.
• W3119492218 cites W2624785543 @default.
• W3119492218 cites W2767447900 @default.
• W3119492218 cites W2785646284 @default.
• W3119492218 cites W2809092065 @default.
• W3119492218 cites W2989019570 @default.
• W3119492218 doi "https://doi.org/10.1186/s12886-020-01757-7" @default.
• W3119492218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7805171" @default.
• W3119492218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33435908" @default.
• W3119492218 hasPublicationYear "2021" @default.
• W3119492218 type Work @default.
• W3119492218 sameAs 3119492218 @default.
• W3119492218 citedByCount "7" @default.
• W3119492218 countsByYear W31194922182021 @default.
• W3119492218 countsByYear W31194922182022 @default.
• W3119492218 countsByYear W31194922182023 @default.
• W3119492218 crossrefType "journal-article" @default.
• W3119492218 hasAuthorship W3119492218A5000602417 @default.
• W3119492218 hasAuthorship W3119492218A5002540731 @default.
• W3119492218 hasAuthorship W3119492218A5020672815 @default.
• W3119492218 hasAuthorship W3119492218A5022949376 @default.
• W3119492218 hasAuthorship W3119492218A5023793303 @default.
• W3119492218 hasAuthorship W3119492218A5028908432 @default.
• W3119492218 hasAuthorship W3119492218A5041792266 @default.
• W3119492218 hasAuthorship W3119492218A5049008273 @default.
• W3119492218 hasAuthorship W3119492218A5075207987 @default.
• W3119492218 hasAuthorship W3119492218A5079525467 @default.
• W3119492218 hasBestOaLocation W31194922181 @default.
• W3119492218 hasConcept C118487528 @default.
• W3119492218 hasConcept C134018914 @default.
• W3119492218 hasConcept C141071460 @default.
• W3119492218 hasConcept C188816634 @default.
• W3119492218 hasConcept C2776268601 @default.
• W3119492218 hasConcept C2776694085 @default.
• W3119492218 hasConcept C2777235844 @default.
• W3119492218 hasConcept C2777802072 @default.
• W3119492218 hasConcept C2778257484 @default.
• W3119492218 hasConcept C2778844676 @default.
• W3119492218 hasConcept C2779829184 @default.
• W3119492218 hasConcept C2780261187 @default.
• W3119492218 hasConcept C2780347916 @default.
• W3119492218 hasConcept C2780827179 @default.
• W3119492218 hasConcept C2781100027 @default.
• W3119492218 hasConcept C2908732032 @default.
• W3119492218 hasConcept C555293320 @default.
• W3119492218 hasConcept C71924100 @default.
• W3119492218 hasConceptScore W3119492218C118487528 @default.
• W3119492218 hasConceptScore W3119492218C134018914 @default.
• W3119492218 hasConceptScore W3119492218C141071460 @default.
• W3119492218 hasConceptScore W3119492218C188816634 @default.
• W3119492218 hasConceptScore W3119492218C2776268601 @default.
• W3119492218 hasConceptScore W3119492218C2776694085 @default.
• W3119492218 hasConceptScore W3119492218C2777235844 @default.
• W3119492218 hasConceptScore W3119492218C2777802072 @default.
• W3119492218 hasConceptScore W3119492218C2778257484 @default.
• W3119492218 hasConceptScore W3119492218C2778844676 @default.
• W3119492218 hasConceptScore W3119492218C2779829184 @default.
• W3119492218 hasConceptScore W3119492218C2780261187 @default.
• W3119492218 hasConceptScore W3119492218C2780347916 @default.
• W3119492218 hasConceptScore W3119492218C2780827179 @default.
• W3119492218 hasConceptScore W3119492218C2781100027 @default.
• W3119492218 hasConceptScore W3119492218C2908732032 @default.
• W3119492218 hasConceptScore W3119492218C555293320 @default.
• W3119492218 hasConceptScore W3119492218C71924100 @default.
• W3119492218 hasIssue "1" @default.
• W3119492218 hasLocation W31194922181 @default.
• W3119492218 hasLocation W31194922182 @default.
• W3119492218 hasOpenAccess W3119492218 @default.
• W3119492218 hasPrimaryLocation W31194922181 @default.
• W3119492218 hasRelatedWork W1668980245 @default.
• W3119492218 hasRelatedWork W1972614420 @default.
• W3119492218 hasRelatedWork W1997095687 @default.
• W3119492218 hasRelatedWork W2023340561 @default.
• W3119492218 hasRelatedWork W2137139667 @default.

• next